Want to work with drug development of an innovative medical product being a living organism?
Ilya Pharma will give a presentation of the latest developments and the coming milestones in Stockholm September 11 2018.
Ilya Pharma celebrates a good year and especially that the last preclinical study in mini pigs was successful and met safety aspects and that the treatment with ILP100 accelerates wound healing and reduces scaring in this model.
Peter Frank now fills the position as Drug Development manager at Ilya Pharma. Peter has a background in the industry of more than fifteen years working with development of biologics. Previous recent positions were at GE Healthcare and Galderma.
SwedenBIO's prize is awarded to a Life Science company that demonstrated successful achievements beyond the usual and that has contributed to increased interest in the industry. This year Ilya Pharma is selected as finalist together with Bioarctic, Galenica, Gedea Biotech, Hansa Medical, Isconova/Novavax, Scandinavian Biopharma, Verigraft, Wilson Therapeutics and Xintela. The jury consists of SwedenBIO's Board and a representative of the year's price sponsor HealthCap.
Evelina Vågesjö participated in a panel discussion with Ann Linde, Sweden´s Minister of EU affairs and trade. The subject was how to strengthen the export potential in the business region Uppsala.
Five promising entrepreneurs from the Nordic countries was selected to participate in a global conference in New York, between the 4th and 9th of March. The focus was how to build a sustainable global company according to the goals UN Development and Sustainability Objectives 2030.
The foundations of ILYA Pharmas successful drug development program stems from high level scientific work.
Uppsala-based Ilya Pharma has been awarded EUR 2.99 million (about SEK 30 million) from the European Commission in the face of tough international competition. The company, which develops next-generation biological drugs for treating wounds in skin and mucous membranes, has thus secured funding to obtain the first clinical data for its new drug candidate.